United Kingdom Archives

News and Trends 1 Sep 2015

Genentech’s Sean Bohen defects to AstraZeneca as CMO

AstraZeneca‘s Senior management team gets reinforced by Sean Bohen, a top executive from Roche‘s subsidiary Genentech. Starting in two weeks, he will push late-stage treatments to the market. It’s been two months since two senior manager left the struggling AstraZeneca. Among them, Briggs Morrison, who left to become new CEO of Syndax. To replace him, […]

September 1, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 29 Aug 2015

Cambridge’s Algal Innovation Center is soon finished!

The European Energetic Algae project explores the potential of algae as an energy source. Its half a million euros Algal Innovation Center in Cambridge will soon scale up the research. The Energetic Algae project, shortly EnAlgae, aims to reduce our reliance on fossil fuels by developing biofuel technologies based on algae. “A lot of people don’t realize […]

August 29, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 24 Aug 2015

Monoclonal Antibodies celebrate their 40th birthday, how were they discovered and changed the world?

It’s been 40 years now since the first monoclonal antibodies have been manufactured by researchers from UK’s Medical Research Council (MRC). Let’s go back to the beginning and see how they became global blockbusters. One cannot imagine today’s medical portfolio without monoclonal antibodies. Checkpoint therapies against cancer, immunosuppressives treating multiple sclerosis, vaccines against everything … […]

August 24, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 24 Aug 2015

Novartis signs $1Bn deal for GSK’s Multiple Sclerosis Antibody

Is this Novartis‘ next blockbuster? The Swiss company has acquired GlaxoSmithKline‘s (GSK) immunosuppressive antibody Ofatumumab for up to $1Bn. The new drug allows Novartis to enter the multiple sclerosis market for the third time. Earlier this year, Novartis purchased GSK’s oncology portfolio for $16 billion (€14Bn), including the fully human monoclonal anitbody Ofatumumab, which is […]

August 24, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 20 Aug 2015

DNA to play an essential role in the future of Computers?

You can do terrific things with DNA – convicting a murderer, confirming the right father … and building computers! As biomolecular computing is ever-growing, scientists from the University of East Anglia found a new way to convert DNA in a switching mechanism. This could be used in new bio-computers built from DNA. The structure of […]

August 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Aug 2015

Milestone in Stem Cell Research: European Researchers grow Millimeter-Long Muscle Fibers!

Stem cell research grows and grows in Europe! For the first time ever, researchers succeded to effectively grow a large number of muscle cells derived from pluripotent stem cells! Researchers from six European countries are participating in the PluriMes project to give a cutting edge to the European stem cell research. Launched in February 2014, […]

August 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Aug 2015

It’s raining cash, Woodford invested more than 75% of its mega €1.1Bn Biotech fund

Cash is floating into Biotech like never before, in the US as well as in Europe. And Woodford just announced he invested over 75% of the total money he raised, so over €800M. Let’s have a look at where the money went into. Neil Woodford is a legendary British Biotech investor who opened a new […]

August 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 11 Aug 2015

AstraZeneca’s Oncology Expansion Continues: MedImmune grabs Inovio’s Cancer Vaccine

The massive expansion of AstraZeneca’s pipeline continues, as its biological subsidiary, MedImmune buys Inovio Pharmaceuticals‘ clinical-stage cancer vaccine that targets cancer caused by the human papillomavirus (HPV). MedImmune, which makes up nearly 50% of AstraZeneca’s pipeline, may spend over $720M (€653M) to bolster its cancer-associated portfolio. HPV is the most commonly sexually transmitted virus and […]

August 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

Oxitec’s revolutionary Genetically Modified Insects acquired by Intrexon for €146M

Oxitec‘s self-limiting gene technique, which is designed to exterminate dangerous insects, has a price now: $160M (€146M). US-based Intrexon absorbed the Oxford University’s spinout with its unique technology to accelerate the crackdown of dengue infections and crop damages. As we reported early this year, Intrexon Corporation recently partnered across diverse markets, all being part of […]

August 10, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Heptares Therapeutics, the GPCR-targeted drug company, and British pharma giant AstraZeneca entered a new collaboration under which AstraZeneca will acquire exclusive global rights on the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate. Tumour cells have evolved mechanisms to evade the immune system, including through the production of a natural molecule called adenosine. By stimulating […]

August 10, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 9 Aug 2015

Fresh Money for a Chlamydia Vaccine Using Synthetic Biology

Prokarium Ltd today announced a new £377k (€534k) funding from SynbiCITE to develop an innovative Chlamydia vaccine using synthetic biology. The new therapy could help the 92 million people affected by Chlamydia each year and help fighting one of the most common sexually transmitted infections. The £498k (€706k) Chlamydia vaccine project is funded at £377k (€534k) from SynbiCITE, the UK’s Innovation and […]

August 9, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 5 Aug 2015

AstraZeneca Adds New Antisense Drugs to its Pipeline

Isis Pharmaceuticals and AstraZeneca extend their collaboration to discover and develop antisense therapies. After cancer, the partners are now targeting cardiovascular, metabolic and renal diseases. Antisense drugs are short, chemically modified, single-stranded nucleic acids (antisense oligonucleotides) that have the ability to target any gene product of interest. They offer new opportunities for therapeutic intervention because […]

August 5, 2015 - 2 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

Genentech’s Sean Bohen defects to AstraZeneca as CMO

Cambridge’s Algal Innovation Center is soon finished!

Monoclonal Antibodies celebrate their 40th birthday, how were they discovered and changed the world?

Novartis signs $1Bn deal for GSK’s Multiple Sclerosis Antibody

DNA to play an essential role in the future of Computers?

Milestone in Stem Cell Research: European Researchers grow Millimeter-Long Muscle Fibers!

It’s raining cash, Woodford invested more than 75% of its mega €1.1Bn Biotech fund

AstraZeneca’s Oncology Expansion Continues: MedImmune grabs Inovio’s Cancer Vaccine

Oxitec’s revolutionary Genetically Modified Insects acquired by Intrexon for €146M

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Fresh Money for a Chlamydia Vaccine Using Synthetic Biology

AstraZeneca Adds New Antisense Drugs to its Pipeline

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!